Pathology of restenosis in saphenous bypass grafts after long-term stent implantation.
The implantation of saphenous vein grafts on the coronary arterial tree eventually leads to graft narrowing, which can be treated by the implantation of intravascular stents. However, long-term restenosis after stent implantation occurs in at least 30% of cases. Ten saphenous bypass grafts, in which a total of 12 stents had been implanted for an average of 32 months, were retrieved at least 10 months after implantation for angiographic diagnosis of reocclusion or severe restenosis. The metal struts were removed after macroscopic inspection of the vein, and the grafts were examined by light microscopy. Angiography revealed total occlusion in 9 stents and severe narrowing in 3. Pathologic examination revealed graft occlusion due to cellular hyperplasia in 4 cases and to recent thrombus formation in 5. Progression of atherosclerotic plaque was the cause of restenosis in the 3 severely narrowed grafts. In 2 of 5 grafts implanted with Palmaz-Schatz stents, the metallic struts had induced a local inflammatory reaction. Therefore, the long-term reocclusion of saphenous bypass grafts after stent implantation may be due to atherosclerotic plaque or fibromuscular hyperplasia. However, thrombus formation may still occur several years after implantation. In specific cases, stent implantation also induces inflammation around the stent struts.
Depre
C
C
Division of Cardiology, University of Louvain Medical School, Brussels, Belgium.
Havaux
X
X
Wijns
W
W
D000199:Actins / Q000378:metabolism; D000368:Aged; D000792:Angiography; D015906:Angioplasty, Balloon, Coronary; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications / Q000378:metabolism; D003327:Coronary Disease / Q000601:surgery; D005352:Fibromuscular Dysplasia / Q000150:complications / Q000378:metabolism; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000473:pathology* / Q000601:surgery; D006801:Humans; D006965:Hyperplasia / Q000150:complications; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000473:pathology; D012008:Recurrence; D012501:Saphenous Vein / Q000378:metabolism / Q000473:pathology* / Q000637:transplantation; D015607:Stents / Q000009:adverse effects*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000097382:CD68 Molecule
D000199:Actins; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014409:Tumor Necrosis Factor-alpha; C067980:CD68 antigen, human; D000097382:CD68 Molecule